Infectious Risks Associated with Biologic Therapies in Autoimmune, Rheumatologic and Dermatologic Diseases: A Narrative Review
Microorganisms · 02.06.2026 · 14 (6) · 1250
DOI: 10.3390/microorganisms14061250 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 02.06.2026. Verfasst von Stefania Capuccio und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy. Die Arbeit nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Biologic and targeted synthetic therapies have substantially improved the management of autoimmune diseases (ADs), achieving unprecedented disease control. However, by modulating key immune pathways, these agents increase susceptibility to a wide spectrum of infections. This narrative review synthesizes current evidence on infectious risks associated with biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) in AD, characterizing infection profiles across different drug classes, identifying patient- and treatment-related risk factors, and providing evidence-based recommendations for screening, prevention, and management. A comprehensive literature search was conducted through March 2026, across PubMed, Embase, and the Cochrane Library, using predefined search terms combining biologic and targeted synthetic drug classes with infection-related outcomes. Evidence from major international registries (BSRBR-RA, DANBIO, RABBIT) and society guidelines (ACR, EULAR, IDSA) was prioritized. Among bDMARDs, TNF-α inhibitors (TNF-α i) and rituximab were associated with the highest rates of serious infections, whereas IL-17 and IL-23 inhibitors demonstrated comparatively lower infectious risk profiles. Steroids, older age, and prior serious infections emerged as the most consistent patient-related risk modifiers. Unlike prior reviews focused on single diseases or drug classes, this work provides an integrated, cross-disciplinary risk stratification framework. bDMARDs and tsDMARDs remain among the most innovative treatments available for effective management of ADs, with favorable benefit–risk profiles when accompanied by systematic prevention strategies. Universal pre-treatment screening for tuberculosis and viral hepatitis, risk-stratified parasitic screening, evidence-based vaccination, and selective antimicrobial prophylaxis can mitigate infectious complications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy.
- Department of Medicine and Surgery, "Kore" University of Enna, 94100 Enna, Italy.
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00161 Rome, Italy.
- Microbiology Department, Pharmacy Faculty, University of Barcelona, 08035 Barcelona, Spain.
- Ruhr University Bochum, Knappschaft Kliniken University Hospital Bochum, Department of Medicine, 44780 Bochum, Germany.
- Division of Anaesthesia, Critical Care, Pain and Emergency Medicine, Nîmes University Hospital, University of Montpellier, 30900 Nîmes, France.
ORCID-Profile: Stefania Capuccio, Antonios Katsounas, Jordi Rello
Zitieren
APA
Capuccio, S., Romano, F., Rello, J. R., Katsounas, A., & Rello, J. (2026). Infectious Risks Associated with Biologic Therapies in Autoimmune, Rheumatologic and Dermatologic Diseases: A Narrative Review. Microorganisms, 14(6), 1250. https://doi.org/10.3390/microorganisms14061250
Vancouver
Capuccio S, Romano F, Rello JR, Katsounas A, Rello J. Infectious Risks Associated with Biologic Therapies in Autoimmune, Rheumatologic and Dermatologic Diseases: A Narrative Review. Microorganisms. 2026;14(6):1250. doi:10.3390/microorganisms14061250
BibTeX
@article{Capuccio2026,
author = {Capuccio, Stefania and Romano, Francesco and Rello, Joan R and Katsounas, Antonios and Rello, Jordi},
title = {Infectious Risks Associated with Biologic Therapies in Autoimmune, Rheumatologic and Dermatologic Diseases: A Narrative Review},
journal = {Microorganisms},
year = {2026},
volume = {14},
number = {6},
pages = {1250},
doi = {10.3390/microorganisms14061250}
}
EUVIMED